Forns, Xavier

Publishing since 1993 (Senior)

Has published 90 publications in 18 years

Number of publications published per year by Forns, Xavier. (Source : PubMed)

Distribution of publications types for Forns, Xavier. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML, Ivorra C, Dominguez M, Conde L, Millán C, Marí M, Colmenero J, Lozano JJ, Jares P, Vidal J, Forns X, Arroyo V, Caballería J, Ginès P, Bataller R. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans.  Hepatology  2010;51;3  
•  Forns X, Bruix J. Treating hepatitis C in patients with cirrhosis: The effort is worth it.  J. Hepatol.  2010  
•  Ramírez S, Pérez-Del-Pulgar S, Carrión JA, Coto-Llerena M, Mensa L, Dragun J, García-Valdecasas JC, Navasa M, Forns X. Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non dominant viral strains.  J. Gen. Virol.  2010  
•  Carrión JA, Fernández-Varo G, Bruguera M, García-Pagán JC, García-Valdecasas JC, Pérez-Del-Pulgar S, Forns X, Jiménez W, Navasa M. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation.  Gastroenterology  2010;138;1  
•  Carrión JA, Torres F, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation.  Hepatology  2010;51;1  
•  Colmenero J, Bataller R, Sancho-Bru P, Dominguez M, Moreno M, Forns X, Bruguera M, Arroyo V, Brenner DA, Ginès P. Effects of Losartan on Hepatic Expression of Non-phagocytic NADPH Oxidase and Fibrogenic Genes in Patients with Chronic Hepatitis C.  Am. J. Physiol. Gastrointest. Liver Physiol.  2009  
•  Balderramo DC, García O, Colmenero J, Espinosa G, Forns X, Ginès P. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C.  Dig Liver Dis  2009;41;7  
•  Ramirez S, Perez-Del-Pulgar S, Carrion JA, Costa J, Gonzalez P, Massaguer A, Fondevila C, Garcia-Valdecasas JC, Navasa M, Forns X. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation.  Am. J. Transplant.  2009;9;7  
•  Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.  J. Hepatol.  2009;50;4  
•  Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, Calleja JL, Ross S, Spangenberg HC, Garcia-Samaniego J, Fuchs M, Enríquez J, Wiegand J, Stern J, Wu K, Kukolj G, Marquis M, Beaulieu P, Nehmiz G, Steffgen J. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment.  Antivir. Ther. (Lond.)  2009;14;1  

[ See timeline ] [ See all publications ]